Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

folitixorin

A folate-based biomodulator with potential antineoplastic activity. Folitixorin stabilizes the covalent binding of the fluorouracil metabolite 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (FdUMP) to its target enzyme, thymidylate synthase, which results in inhibition of thymidylate synthase, depletion of thymidine triphosphate (TTP), a necessary constituent of DNA, and tumor cell death. Unlike leucovorin, folitixorin, as the active form of folate, does not require metabolic activation and may increase the chemotherapeutic effects of fluorouracil with lower toxicity.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:5,10 methylenetetrahydrofolate
5,10-methylenetetrahydrofolate
US brand name:CoFactor
Abbreviation:5,10-MTHF
MTHF
Code name:ANX-510
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search